INMB Stock Overview
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
INmune Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.80 |
| 52 Week High | US$14.74 |
| 52 Week Low | US$6.50 |
| Beta | 1.95 |
| 1 Month Change | -19.56% |
| 3 Month Change | -22.40% |
| 1 Year Change | 10.69% |
| 3 Year Change | -28.98% |
| 5 Year Change | -16.98% |
| Change since IPO | 10.14% |
Recent News & Updates
Recent updates
Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
Dec 02INmune Bio A No-Brainer Investment
Oct 13INmune Bio: High-Risk High-Reward Alzheimer's Play
Aug 18Our Bullish Take On INmune Bio's Drug Pipeline
Aug 12INmune Bio: Underfollowed AD Player With Very Bullish August Momentum
Jul 13Companies Like INmune Bio (NASDAQ:INMB) Are In A Position To Invest In Growth
Jun 25INmune enters $15M credit facility to fund purchase of Xencor option
Jun 14INmune Bio (NASDAQ:INMB) Is In A Strong Position To Grow Its Business
Mar 01What Kind Of Investors Own Most Of INmune Bio, Inc. (NASDAQ:INMB)?
Jan 05
Here's Why We're Not Too Worried About INmune Bio's (NASDAQ:INMB) Cash Burn Situation
Dec 01INmune Bio EPS misses by $0.19
Nov 05Shareholder Returns
| INMB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.6% | -4.2% | -3.7% |
| 1Y | 10.7% | -2.0% | 20.5% |
Return vs Industry: INMB exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: INMB underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| INMB volatility | |
|---|---|
| INMB Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INMB's share price has been volatile over the past 3 months.
Volatility Over Time: INMB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 14 | RJ Tesi | www.inmunebio.com |
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers.
INmune Bio, Inc. Fundamentals Summary
| INMB fundamental statistics | |
|---|---|
| Market cap | US$158.63m |
| Earnings (TTM) | -US$30.01m |
| Revenue (TTM) | US$155.00k |
1,023x
P/S Ratio-5.3x
P/E RatioIs INMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INMB income statement (TTM) | |
|---|---|
| Revenue | US$155.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$155.00k |
| Other Expenses | US$30.16m |
| Earnings | -US$30.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | 100.00% |
| Net Profit Margin | -19,360.00% |
| Debt/Equity Ratio | 26.0% |
How did INMB perform over the long term?
See historical performance and comparison